Citatuzumab bogatox

{{Short description|Pharmaceutical drug}}

{{cs1 config|name-list-style=vanc|display-authors=6}}

{{Drugbox

| Verifiedfields = changed

| Watchedfields = changed

| verifiedrevid = 458638803

| image =

| type = mab

| mab_type = Fab

| source = zu/o

| target = TACSTD1

| tradename =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 945228-49-9

| ATC_prefix = none

| ATC_suffix =

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| UNII_Ref = {{fdacite|changed|FDA}}

| UNII = 23J303Z5CA

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| C=3455 | H=5371 | N=921 | O=1060 | S=18

}}

Citatuzumab bogatox (VB6-845) is a monoclonal antibody Fab fragment fused with bouganin,{{cite journal | vauthors = Eyvazi S, Farajnia S, Dastmalchi S, Kanipour F, Zarredar H, Bandehpour M | title = Antibody Based EpCAM Targeted Therapy of Cancer, Review and Update | journal = Current Cancer Drug Targets | volume = 18 | issue = 9 | pages = 857–868 | date = 2018 | pmid = 29295696 | doi = 10.2174/1568009618666180102102311 }} a ribosome inactivating protein from the plant Bougainvillea spectabilis.[https://www.who.int/entity/medicines/publications/druginformation/issues/INN-PList-No99.pdf International Nonproprietary Names for Pharmaceutical Substances (INN)], World Health Organization. It has undergone preclinical development for the treatment of ovarian cancer and other solid tumors.{{cite web | url = http://www.viventia.com/vb6.html | work = Viventia Biotech Inc. | title = VB6-845 | archive-url = https://web.archive.org/web/20100329171426/http://www.viventia.com/vb6.html | archive-date = 29 March 2010 }}